Polen Capital: 27 Novo Nordisk transactions (Polen Capital Management

27 Polen Capital Novo Nordisk Trades

Polen Capital acquired 1 Million Novo Nordisk shares worth $67.8 Million. That's 0.20% of their equity portfolio (33rd largest holding). The first Novo Nordisk trade was made in Q2 2013. Since then Polen Capital bought shares eighteen more times and sold shares on eight occasions. The investor's estimated purchase price is $164 Million, resulting in a loss of 59%.

Avg closing price

Price range

Sold 84.4% shares (-5.4 Million shares) Q1 2025

Avg closing price $82.50

Price range $69.30 - $90.95

Sold 6.5% shares (-449 Thousand shares) Q4 2024

Avg closing price $106.90

Price range $85.00 - $120.04

Sold 8.0% shares (-593 Thousand shares) Q3 2024

Avg closing price $133.54

Price range $119.07 - $145.42

Sold 4.1% shares (-321 Thousand shares) Q2 2024

Avg closing price $132.51

Price range $122.71 - $146.91

Sold 2.4% shares (-190 Thousand shares) Q1 2024

Avg closing price $119.04

Price range $102.11 - $135.92

Increased shares by 0.7% (+52.2 Thousand shares) Q4 2023

Avg closing price $98.89

Price range $87.78 - $105.45

New holding (+7.91 Million shares) Q3 2023

Avg closing price $164.52

Price range $90.94 - $199.54

Sold -238 Thousand shares Q1 2020

Avg closing price $59.55

Price range $49.46 - $64.78

Increased shares by 71.8% (+99.3 Thousand shares) Q4 2019

Avg closing price $55.37

Price range $49.86 - $58.26

Increased shares by 16.5% (+19.6 Thousand shares) Q3 2019

Avg closing price $50.57

Price range $47.54 - $53.43

Increased shares by 29.1% (+26.8 Thousand shares) Q2 2019

Avg closing price $49.42

Price range $46.79 - $52.47

Increased shares by 44.9% (+28.5 Thousand shares) Q1 2019

Avg closing price $49.15

Price range $46.36 - $52.63

Increased shares by 23.2% (+11.9 Thousand shares) Q4 2018

Avg closing price $44.44

Price range $41.54 - $47.25

Increased shares by 5.0% (+2.46 Thousand shares) Q3 2018

Avg closing price $48.80

Price range $46.76 - $51.24

Increased shares by 9.3% (+4.17 Thousand shares) Q2 2018

Avg closing price $47.53

Price range $44.29 - $50.42

Increased shares by 19.8% (+7.43 Thousand shares) Q1 2018

Avg closing price $52.50

Price range $48.49 - $58.14

Increased shares by 6.8% (+2.39 Thousand shares) Q4 2017

Avg closing price $50.86

Price range $47.53 - $53.73

Increased shares by 5.2% (+1.74 Thousand shares) Q3 2017

Avg closing price $45.19

Price range $41.15 - $49.22

Sold 1.4% shares (-480 shares) Q2 2017

Avg closing price $40.35

Price range $34.36 - $44.44

Increased shares by 7.1% (+2.25 Thousand shares) Q1 2017

Avg closing price $34.82

Price range $32.98 - $37.06

News about Novo Nordisk - ADR and Polen Capital

BMO's Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly

Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to the departure of Novo Nordisk's CE...

youtube.com, about 1 month ago

Novo Nordisk A/S (NVO) Q2 2024 Earnings Call Transcript

Novo Nordisk A/S (NVO) Q2 2024 Earnings Conference Call August 7, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations ...

seekingalpha.com, 11 months ago

KKR, Novo Nordisk, others bid for Healthium buy

Global PE major KKR and pharma major Novo Nordisk have submitted final bids for Healthium. A third, joint bid has come from India-focused PE firm ChrysCapita...

Livemint, about 1 year ago